Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Priscilla Hollander,Jie Liu,Julie S. Hill,Jeremy Johnson,Zhi-wei Jiang,Gregory T. Golm,Susan Huyck,Steven G. Terra,James P. Mancuso,Samuel S. Engel,Brett Lauring

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

2018

Priscilla Hollander
Jie Liu
Julie S. Hill
Jeremy Johnson
Zhi-wei Jiang
Gregory T. Golm
Susan Huyck
Steven G. Terra
James P. Mancuso
Samuel S. Engel
Brett Lauring

Introduction This study assessed the safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs. glimepiride in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin.

Keywords:

Endocrinology
Randomized controlled trial
Ertugliflozin
Sodium-Glucose Cotransporter 2 Inhibitor
Diabetes mellitus
Internal medicine
Metformin
Type 2 Diabetes Mellitus
Glimepiride
Sulfonylurea
Medicine
Pharmacology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations